Category Archives: TRIPS

Opinion: WTO should waive TRIPS provisions during COVID-19

Posted on November 28, 2020 by donttradeourlivesaway

Source: Managing IP The WTO should adopt India and South Africa’s proposal to lift IP restrictions to ensure access to COVID vaccines and therapies The world received some good news this month. Two novel mRNA vaccines have shown to be … Continue reading →

Posted in Access to Medecines, COVID-19, TRIPS, TRIPS&IP rights | Leave a comment

Third World Network reports on 20th Nov 2020 TRIPS Council discussion on the Waiver Proposal initiated by India and South Africa

Posted on November 24, 2020 by donttradeourlivesaway

24 Nov 2020 Source: TWN On 20th Nov 2020, TRIPS Council had an informal meeting that was open only to members and Observers in WTO and discussed the Waiver Proposal initiated by India and South Africa. The discussion will continue … Continue reading →

Posted in Access to Medecines, COVID-19, Diseases/Therapies, TRIPS, TRIPS&IP rights | Leave a comment

Developing Nations Push for Covid-19 Vaccines Without the Patents

Posted on November 24, 2020 by donttradeourlivesaway

17 Nov 2020 Source: WSJ South Africa and India plan to argue at the WTO that the usual protections should be suspended in light of the pandemic ISLAMABAD, Pakistan—A group of developing countries, led by South Africa and India, say … Continue reading →

Posted in Access to Medecines, COVID-19, TRIPS, Vaccines, WTO | Leave a comment

TRIPS Debated As WHO Board Reaches Agreement On Universal Health Coverage

Posted on February 6, 2019 by donttradeourlivesaway

Source: IP Watch 6th Feb 2019 World Health Organization Board members agreed last week on a draft resolution for the preparation of a United Nations General Assembly high-level meeting on universal health coverage in the fall, following intensive closed consultations … Continue reading →

Posted in Access to Medecines, TRIPS, TRIPS flexibilities, Universal Health Coverage | Leave a comment

Switzerland should stop pushing for TRIPS-plus measures in trade agreement with Indonesia

Posted on November 20, 2018 by donttradeourlivesaway

20th Nov 2018, New Delhi Source: Public Eye Swiss and Norwegians civil society groups led by Public Eye and Third World Network addressed on September 11, 2018, their serious concerns in an open letter to their Minister of Trade over … Continue reading →

Posted in TRIPS, TRIPS plus, TRIPS&IP rights | Leave a comment

Canadian generic drugmakers find fault with USMCA

Posted on October 3, 2018 by donttradeourlivesaway

Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading →

Posted in Biologics/Biosimilars, Data Exclusivity, USMCA | Leave a comment

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

Posted on August 2, 2018 by donttradeourlivesaway

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading →

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Here’s the short note on UNHLM on TB and US pressurising to dilute TRIPS flexibilities

Posted on July 20, 2018 by donttradeourlivesaway

The United Nations is going to hold a High Level Meeting on TB in New York in September. The member countries of UN will sign on a declaration will set the direction in which work on TB, globally, will move. … Continue reading →

Posted in TRIPS, TRIPS flexibilities, Tuberculosis (TB), US Pressure | Leave a comment

The grounds for opposing patent applications for velpatasvir

Posted on July 10, 2018 by donttradeourlivesaway

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading →

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

Posted on June 29, 2018 by donttradeourlivesaway

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading →

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment